Pseudotumor Cerebri Rate Rises With Obesity

BY NANCY A. MELVILLE
Contributing Writer

Scottsdale, Ariz. — The incidence of pseudotumor cerebri is rising among the obese, with keep this relatively uncommon condition in mind when obese patients present with symptoms resembling brain tumor or intracranial pressure, said Deborah Friedman, M.D., at the American Headache Society’s 2004 Headache Symposium.

Pseudotumor cerebri is primarily seen in obese women of childbearing age, and although the condition affects only 1 in 100,000 people in the United States, the rate for obese women between the ages of 20 and 44 is about 19 per 100,000.

In women with higher levels of obesity, however, pseudotumor cerebri is being seen more frequently.

In Mississippi, called the most overweight state in the nation because a quarter of its population is considered obese by BMI criteria, the incidence of pseudotumor cerebri in the overall population is double, at 2 per 100,000, and among obese women aged 20-44, the rate is about 25 per 100,000.

Large increases in pseudotumor cerebri incidence rates have also been noted in men, whose weight did not change. For men who gained more than 35 pounds after age 18, versus those whose weight held steady, the relative risk was 1.70 in NHS I and 1.82 in NHS II.

Body mass index (BMI) also was a factor. In men, the relative risk of stone formation was 1.33 with a BMI of 30 kg/m² or higher, compared with men who had a BMI of 21-22.9 kg/m². For women, the same BMI categories were associated with a relative risk of 1.90 in NHS I and 2.09 in NHS II.

For men with a waist circumference greater than 45 inches, the relative risk was 1.48, compared with those whose waist circumference was less than 34 inches. The relative risk for women with a waist circumference greater than 40 inches versus women with a waist circumference less than 31 inches was 1.71 in the older women and 1.94 in the younger women.

Diets and Cardiac Risk Factors

For popular diets all appear to reduce body weight and several cardiac risk factors at 1 year, but the benefits are modest, apparently because of low adherence, said Michael Dr. Dansinger, M.D., of Tufts–New England Medical Center, Boston.

In a single-center, randomized trial of adults with a BMI of 35 kg/m² and at least one metabolic cardiac risk factor, 160 patients were evenly divided among the diets: Atkins (carbohydrate restriction), Zone (monounsaturated fatty acids), Weight Watchers (calorie restriction), or Ornish (fat restriction). For the first 2 months, patients were told to make a maximum effort to adhere to the diet. At 2 months, 21% had dropped out; the percentage rose to 38% at 6 months and 42% at 1 year (JAMA 2005;293:43-53).

In the primary intent-to-treat analysis, mean weight loss at 1 year was 4.8 pounds for Atkins (52% completed the study), 6 pounds for Zone (65% completed), 4.9 pounds for Weight Watchers (65% completed), and 7.3 pounds for Ornish (50% completed). There was no significant difference between diets.

All four diets modestly reduced mean LDL-cholesterol levels at 1 year, except for Atkins. All diets significantly increased mean HDL-cholesterol levels, except for Ornish. The LDL/HDL ratio fell about 10% at 1 year. There were no effects on triglycerides, blood pressure, or fasting glucose.

Poor sustainability and adherence rates resulted in modest weight loss and cardiac risk factor reductions,” the researchers said.

Protecting Bone During Dieting

Even modest weight loss from exercise training is associated with a reduction in bone mineral density (BMD), particularly in women who are not taking rifaloxin or hormone therapy (HT), reported Weldon S. Gozansky, M.D., of the University of Colorado, Denver.

In a 6-month, randomized double-blind, placebo-controlled study of postmenopausal, sedentary, overweight women aged 50-70 years, 68 participated in a supervised exercise training program of moderate intensity and 26 control subjects did not participate. Both groups were separately randomized to one of three treatment groups: placebo, rifaloxin, or HT (J. Clin. Endocrinol. Metab. 2005;90:52-9).

Women in the control group had a mean weight gain of 0.8 kg; those in the intervention group had a mean loss of 4.1 kg. In the control group, the average percent change in BMD across all measured skeletal sites was a 0.6% reduction in placebo users (n = 7), a 0.9% gain in rifaloxin users (n = 9), and a 3.0% gain in HT users. In the intervention group, BMD declined 1.5% in the placebo group (n = 22), fell 0.5% in the rifaloxine group (n = 23), and rose 1.1% in the HT group (n = 22).

“Rifaloxin weight loss does not necessarily confer protection against low BMD in postmenopausal women,” the researchers said.

—Kevin Foley

Clinical Capsules

Obesity and Risk of Kidney Stones

Obesity and weight gain may increase the risk of kidney stone formation, especially in women with a waist circumference greater than 150 pounds. When comparing the same BMI categories were associated with a relative risk of 1.90 in NHS I and 2.09 in NHS II.

The relative risk for women with a waist circumference was less than 34 inches. The relative risk for men with a waist circumference greater than 45 inches, the relative risk was 1.48, compared with those whose waist circumference was less than 34 inches. The relative risk for women with a waist circumference greater than 40 inches versus women with a waist circumference less than 31 inches was 1.71 in the older women and 1.94 in the younger women.

Diets and Cardiac Risk Factors

For popular diets all appear to reduce body weight and several cardiac risk factors at 1 year, but the benefits are modest, apparently because of low adherence, said Michael Dr. Dansinger, M.D., of Tufts–New England Medical Center, Boston.

In a single-center, randomized trial of adults with a BMI of 35 kg/m² and at least one metabolic cardiac risk factor, 160 patients were evenly divided among the diets: Atkins (carbohydrate restriction), Zone (monounsaturated fatty acids), Weight Watchers (calorie restriction), or Ornish (fat restriction). For the first 2 months, patients were told to make a maximum effort to adhere to the diet. At 2 months, 21% had dropped out; the percentage rose to 38% at 6 months and 42% at 1 year (JAMA 2005;293:43-53).

In the primary intent-to-treat analysis, mean weight loss at 1 year was 4.8 pounds for Atkins (52% completed the study), 6 pounds for Zone (65% completed), 4.9 pounds for Weight Watchers (65% completed), and 7.3 pounds for Ornish (50% completed). There was no significant difference between diets.

All four diets modestly reduced mean LDL-cholesterol levels at 1 year, except for Atkins. All diets significantly increased mean HDL-cholesterol levels, except for Ornish. The LDL/HDL ratio fell about 10% at 1 year. There were no effects on triglycerides, blood pressure, or fasting glucose.

Poor sustainability and adherence rates resulted in modest weight loss and cardiac risk factor reductions,” the researchers said.

Protecting Bone During Dieting

Even modest weight loss from exercise training is associated with a reduction in bone mineral density (BMD), particularly in women who are not taking rifaloxin or hormone therapy (HT), reported Weldon S. Gozansky, M.D., of the University of Colorado, Denver.

In a 6-month, randomized double-blind, placebo-controlled study of postmenopausal, sedentary, overweight women aged 50-70 years, 68 participated in a supervised exercise training program of moderate intensity and 26 control subjects did not participate. Both groups were separately randomized to one of three treatment groups: placebo, rifaloxin, or HT (J. Clin. Endocrinol. Metab. 2005;90:52-9).

Women in the control group had a mean weight gain of 0.8 kg; those in the intervention group had a mean loss of 4.1 kg. In the control group, the average percent change in BMD across all measured skeletal sites was a 0.6% reduction in placebo users (n = 7), a 0.9% gain in rifaloxin users (n = 9), and a 3.0% gain in HT users. In the intervention group, BMD declined 1.5% in the placebo group (n = 22), fell 0.5% in the rifaloxine group (n = 23), and rose 1.1% in the HT group (n = 22).

“Rifaloxin weight loss does not necessarily confer protection against low BMD in postmenopausal women,” the researchers said.

—Kevin Foley

In Uncomplicated Obesity Aortic Elasticity Is Lowered

BY BRUCE JANCIN
Denver Bureau

New Orleans — Obese individuals with no other complicating diseases have an abnormally stiff aorta, predisposing them to heart failure and other cardiovascular diseases, Monique Robinson, M.B., said at the annual scientific sessions of the American Heart Association.

“The take-home message is this: Being just overweight or obese is not OK. I think in primary care practice, our focus has been on the comorbidities associated with obesity.

We treat you if you’re diabetic. We treat you if you’ve got hypertension. We also need to treat our obese people who are just obese, because our results suggest that there may be an increased cardiovascular risk for these patients,” said Dr. Robinson, a cardiovascular research fellow at the University of Oxford, England.

Using MRI, she investigated the mechanical elastic functioning of the aorta in 27 obese subjects with a mean body mass index of 44 kg/m² without diabetes, hypercholesterolemia, or hypertension, and in 12 normal-weight controls.

Mean aortic stiffness was reduced by 59% in obese subjects, compared with normal-weight subjects. Mean aortic compliance was mass index, leptin, and HDL cholesterol were all robust predictors of aortic elastic function in obese individuals.

Dr. Robinson and her Oxford colleagues are focusing on leptin, a hormone produced by fat cells, as the most likely chief mechanism by which obesity results in increased aortic stiffness.

Hyperleptinemia is a hallmark of obesity, and leptin has previously been shown to stimulate increased levels of tumor necrosis factor-alpha and other cytokines that can increase vascular tone and thereby reduce elasticity.